Lateral flow test evaluation for Covid-19
Research type
Research Study
Full title
Evaluation of the diagnostic performance of the Rapid SARS-CoV-2 Antigen Test Card for Covid-19
IRAS ID
311335
Contact name
Marco Lee
Contact email
Sponsor organisation
Sante Group
ISRCTN Number
ISRCTN12682933
Duration of Study in the UK
0 years, 1 months, 0 days
Research summary
The global Covid-19 pandemic has affected many lives, causing death, respiratory illness, and cardiovascular complications. High scale testing for the virus in the population and tracing the contacts of people who have tested positive to advise them to self-isolate have been paramount in slowing the epidemic spread of the virus in the United Kingdom. Lateral flow tests are commonly used to diagnose the presence of SARS-Cov-2, the virus that causes Covid-19. It works by detecting proteins from the virus in nasal secretions. If the test is positive, it may mean the presence of the virus in the individual. However, a lateral flow test is not 100% accurate. A positive lateral flow test is commonly followed by a PCR test which is the most accurate test to diagnose the presence of the virus.
In this study, we would like to determine the accuracy of a new lateral flow test called the Rapid SARS-CoV-2 Antigen Test Card by comparing its performance to PCR on Cepheid platform.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
22/EE/0027
Date of REC Opinion
28 Jan 2022
REC opinion
Further Information Favourable Opinion